Status ongoing projects

Glactone Pharma

(Immuno-oncology)

 
Exit
Phase II/III
Phase I
Preclinical

Glactone Pharma develops novel drugs that directly target the oncogenic transcription factor STAT3, currently in preclinical phase. Glactone is investigating the potential of combining its STAT3 inhibitors with existing immunotherapies to treat cancers that are resistant or respond poorly to existing immuno-therapeutic treatments. STAT3 is an ideal target in combination treatments of therapy resistant cancers, for example prostate cancer, with the possibility to expand the project to multiple cancer indications.

More information at the Glactone Pharma website.

Oncorena

(Kidney cancer)

 
Exit
Phase II/III
Phase I
Preclinical

Oncorena develops a drug based on the natural substance orellanine, a highly kidney specific toxin from certain mushrooms. The therapeutic concept is to expose patients with metastasized renal clear cell cancer in dialysis (who cannot be cured by surgery) to orellanine. Hereby the metastases will be destroyed. The ambition is to create a long-term survival benefit for the patients.

Oncorena’s pre-clinical orellanine-studies will be completed in the spring of 2017. The clinical study is expected to start during the third quarter of 2017. The current plan is to conduct the clinical trials at clinics in Sweden and the US enrolling patients with metastatic renal cancer in dialysis.

More information at the Oncorena website.


Adenovir Pharma

(Eye infection)

 
Exit
Phase II/III
Phase I
Preclinical

Adenovir Pharma is developing a topical antiviral pharmaceutical product for treatment of EKC by preventing adenoviruses from binding to the receptors in the human eye. Epidemic keratoconjunctivitis (EKC) is a serious and very contagious eye infection disease. The innovative product – eye drops – acts as “molecular wipes” outside the human cells which should reduce the risk of developing viral resistance. The drug candidate has proved to be well tolerated and safe in preclinical and clinical phase 1 studies and the results from a phase 2 study is soon to be communicated.

More information at the Adenovir Pharma website.

Laccure

(Bacterial vaginosis)

 
Exit
CE mark
Clinical
Preclinical

Laccure has developed Laccure® Pessary that is a breakthrough non-prescription women’s health product that is effective, safe and user-friendly for the treatment and prevention of bacterial vaginosis. Laccure® Pessary is based on a proprietary substance that releases lactic acid over several days to decrease the elevated vaginal pH. In clinical studies 80 % of the women were free from bacterial vaginosis after a single dose. Laccure® Pessary is CE-marked as a Class IIa medical device and is ready for market introduction in the EU/EES countries.

More information at the Laccure website.


Trophea

(Skin atrophy)

 
Exit
Phase II/III
Phase I
Preclinical

Trophea is addressing the medical need for an effective treatment of skin atrophy caused by long-term use of topical glucocorticoids. The project is based on an innovative combination of two well-known and studied ingredients that seem to offer positive synergistic efficacy on skin atrophy. Trophea is in a start-up phase.

Belina

(Breast cancer)

 
Exit
Phase II/III
Phase I
Preclinical

Belina is developing a new improved treatment for breast cancer. Scientists from Lund University have shown that a parallel long-term treatment with a specific drug substance in combination with today’s breast cancer treatment regimens can lead to a significantly improved treatment outcome. Belina is in a start-up phase.